These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 27784340)
1. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340 [TBL] [Abstract][Full Text] [Related]
2. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909 [TBL] [Abstract][Full Text] [Related]
3. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683 [TBL] [Abstract][Full Text] [Related]
4. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043 [TBL] [Abstract][Full Text] [Related]
5. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516 [TBL] [Abstract][Full Text] [Related]
6. An oncolytic adenovirus co-expressing a bi-specific T cell engager and IL-2 for the treatment of ovarian cancer. Ayele K; Wakimoto H; Saha D Mol Ther; 2024 Sep; 32(9):2810-2813. PubMed ID: 39178849 [No Abstract] [Full Text] [Related]
7. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Fu X; Tao L; Zhang X Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099 [TBL] [Abstract][Full Text] [Related]
9. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053 [TBL] [Abstract][Full Text] [Related]
10. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860 [TBL] [Abstract][Full Text] [Related]
11. Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer. Hu Z; Li Y; Yang J; Liu J; Zhou H; Sun C; Tian C; Zhu C; Shao M; Wang S; Wei L; Liu M; Li S; Wang J; Xu H; Zhu W; Li X; Li J Sci Rep; 2024 Oct; 14(1):23671. PubMed ID: 39389985 [TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907 [TBL] [Abstract][Full Text] [Related]
13. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870 [TBL] [Abstract][Full Text] [Related]
15. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model. Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948 [TBL] [Abstract][Full Text] [Related]
16. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026 [TBL] [Abstract][Full Text] [Related]
17. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Du W; Seah I; Bougazzoul O; Choi G; Meeth K; Bosenberg MW; Wakimoto H; Fisher D; Shah K Proc Natl Acad Sci U S A; 2017 Jul; 114(30):E6157-E6165. PubMed ID: 28710334 [TBL] [Abstract][Full Text] [Related]
18. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology. Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741 [TBL] [Abstract][Full Text] [Related]
19. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy. Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R Front Immunol; 2024; 15():1375413. PubMed ID: 38895115 [TBL] [Abstract][Full Text] [Related]
20. Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL Front Immunol; 2021; 12():610042. PubMed ID: 33679747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]